Goldman Sachs reiterated their Conviction Buy List rating and $22 price target on Pfizer (NYSE: PFE) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE